Latest Regulatory Milestones News

Rhythm Biosciences has achieved a significant regulatory milestone with NATA accreditation for its ColoSTAT® blood-based colorectal cancer test, enabling its commercial rollout in Australia and strengthening reimbursement prospects.

The NSW Department of Planning and Environment has approved a six-year extension for the Dartbrook underground coal mine, pushing its operational horizon to 2033 despite ongoing financial administration challenges.

AKORA Resources has secured a 25-year mining permit for its high-grade Bekisopa iron ore project in Madagascar, marking a pivotal step from exploration to development and unlocking new financing and partnership opportunities.

Island Pharmaceuticals has entered a pivotal research agreement with USAMRIID and the Geneva Foundation to accelerate FDA approval of Galidesivir for Marburg Virus Disease, leveraging top-tier US biodefense expertise.

Control Bionics has secured a key regulatory milestone with its NeuroNode device now eligible for reimbursement under Germany’s statutory health insurance, paving the way for expanded European distribution.

Bio-Gene Technology Limited reports strong progress in toxicology studies for Flavocide, targeting its first regulatory submission in Australia by March 2027. This milestone sets the stage for global registrations of the novel insecticide with a new mode of action.

Maronan Metals has been granted a Mineral Development Licence for its Maronan Silver Project, marking a pivotal step toward mine readiness and enabling underground resource expansion.

Vysarn Limited has reported a record half-year financial performance for 1HFY26, with net profit before tax soaring 92% year-on-year. The company reaffirms its $20 million NPBT target for FY26, underpinned by strong growth across all business segments and strategic project progress.

PainChek Limited reported a half-year loss of AUD 4.7 million but achieved a major regulatory milestone with FDA clearance for its Adult App, unlocking significant US market opportunities. The company also completed a share consolidation and raised capital to support growth.

Racura Oncology reported a $4.1 million loss for H1 FY26, reflecting heavy investment in clinical trials and intellectual property. The company also boosted cash reserves through capital raises and rebranded from Race Oncology.

Memphasys Limited has advanced its Felix™ System commercial rollout with key regulatory approvals and new international contracts, while trimming operating costs and narrowing losses in the first half of FY2026.

Lumos Diagnostics reported a 74% increase in its half-year loss to US$4.88 million, despite strong progress with its FebriDx diagnostic test and a landmark US distribution agreement. The company awaits a critical FDA decision that could unlock significant revenue growth.